Sermorelin for Pediatric Growth
Pediatric Growth Peptides
29 Amino Acids
Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH 1-29), the shortest sequence that retains full biological activity at the GHRH receptor.
Halmos et al., GHRH-R and Its Signaling, 2025
Halmos et al., GHRH-R and Its Signaling, 2025
View as imageSermorelin was the first growth hormone-releasing hormone (GHRH) analog approved by the FDA for treating children with growth hormone deficiency. Approved in 1997 and discontinued by its manufacturer in 2008 for commercial reasons, sermorelin occupied a brief but instructive window in pediatric endocrinology. It worked by stimulating the child's own pituitary gland to produce growth hormone, rather than replacing the hormone directly with injections of recombinant human GH (rhGH). That distinction matters because it preserves the natural pulsatile pattern of GH secretion and maintains the negative feedback loop through somatostatin. For the broader landscape of peptide-based approaches to short stature, see Short Stature and Peptide Therapy: What the Evidence Supports.
Key Takeaways
- Sermorelin (GHRH 1-29) was FDA-approved in 1997 for diagnostic testing and treatment of pediatric growth hormone deficiency; it is a 29-amino-acid synthetic fragment of the 44-amino-acid endogenous GHRH that retains full receptor binding activity (Halmos et al., 2025)
- In clinical trials, sermorelin 30 mcg/kg/day given subcutaneously at bedtime produced sustained increases in height velocity over 12 months, with limited data suggesting the effect persisted through 36 months of treatment (Kemp & Frindik, BioDrugs, 1999)
- Sermorelin's height velocity increases were consistently less than those achieved with equimolar doses of recombinant human growth hormone (somatropin), making it a second-line option for children who needed maximum growth acceleration
- The drug was discontinued in 2008 for commercial reasons, not safety concerns; no serious adverse events beyond injection site reactions and transient facial flushing were reported across clinical trials
- Sermorelin requires intact pituitary function: it can only treat growth hormone deficiency caused by hypothalamic dysfunction, not pituitary aplasia, damage, or tumor resection (Kemp & Frindik, 1999)
- Marshall et al. (1996) demonstrated that episodic GHRH administration was more effective than continuous infusion for stimulating GH release, informing the once-nightly dosing strategy used in sermorelin's clinical program
What sermorelin is
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous human GHRH, which is a 44-amino-acid peptide produced by the arcuate nucleus of the hypothalamus. The 1-29 fragment was identified as the minimum sequence required for full biological activity at the GHRH receptor (GHRHR) on pituitary somatotroph cells. Halmos et al. (2025) reviewed the GHRH receptor and its signaling pathways, confirming that GHRH receptor activation triggers a Gs-protein/adenylyl cyclase/cAMP cascade that opens calcium channels, leading to GH exocytosis from somatotroph granules.[1]
Two features of sermorelin's mechanism distinguish it from direct GH replacement. First, somatostatin provides a natural brake on sermorelin's action. When circulating GH and IGF-1 rise, somatostatin increases and suppresses further GHRH-stimulated GH release. This feedback loop makes GH overproduction from sermorelin essentially impossible at therapeutic doses, a safety advantage over rhGH where supraphysiological GH levels can occur with dosing errors. De Vries et al. (2025) detailed the interplay between dopamine, GHRH, and somatostatin in controlling GH secretion, showing that multiple neuroendocrine circuits modulate the response to GHRH stimulation.[2]
Second, sermorelin stimulates pituitary somatotroph proliferation and GH gene transcription, theoretically increasing pituitary GH reserve over time. This contrasts with exogenous rhGH, which suppresses endogenous GH production through negative feedback. Whether this difference has long-term clinical consequences in children remains unproven, as the drug was not studied long enough for firm conclusions.
For the closely related but structurally modified GHRH analog, see CJC-1295: The Growth Hormone Releasing Hormone Analog Explained. For the difference between GHRH analogs and ghrelin-type secretagogues, see GHRP-2 vs GHRP-6: How Two Growth Hormone Peptides Differ.
Clinical evidence in children
Height velocity data
The pivotal clinical data for sermorelin in pediatric GHD came from studies conducted in the 1990s. Children with idiopathic GHD received sermorelin 30 mcg/kg body weight per day via subcutaneous injection at bedtime (timed to coincide with the natural nocturnal GH surge). Over 12 months, treated children showed increases in height velocity from baseline, with a majority experiencing catch-up growth.
The 36-month extension data, available for a smaller subset of children, suggested that the growth acceleration was maintained with continued treatment, though the rate of height velocity gain tapered after the first year, a pattern also seen with rhGH therapy.
Marshall et al. (1996) provided a key pharmacological insight: episodic GHRH administration produced greater GH release than continuous infusion. In a study of children with short stature, pulsatile subcutaneous GHRH (0.5-1.0 mcg/kg every 3 hours) was more effective at stimulating GH secretion than the same total daily dose given as a continuous infusion. This finding supported the once-nightly dosing schedule for sermorelin, mimicking the natural pulsatile GHRH release pattern.[3]
Comparison with recombinant growth hormone
Head-to-head comparisons consistently showed that sermorelin produced less growth acceleration than rhGH at comparable doses. Height velocity increases with sermorelin 30 mcg/kg/day were inferior to somatropin 30 mcg/kg/day. This was expected: sermorelin depends on functional somatotroph cells to produce GH, so the maximum achievable GH output is limited by the child's pituitary capacity. rhGH bypasses this limitation entirely.
This efficacy gap was the central clinical problem. For children with severe GHD and markedly suppressed growth velocities (below the 1st percentile), rhGH was clearly superior. Sermorelin was better suited for children with partial or mild GHD, where the pituitary retained meaningful GH secretory capacity. The distinction depended on accurate diagnosis of the cause and severity of GH deficiency, which is itself challenging in pediatric endocrinology.
Diagnostic application
Sermorelin also had an FDA-approved diagnostic use. The sermorelin (GHRH) stimulation test involved intravenous administration of sermorelin 1 mcg/kg with subsequent measurement of GH response. A normal GH peak indicated intact pituitary function, suggesting hypothalamic dysfunction as the cause of GH deficiency. A blunted response suggested pituitary disease.
This test had fewer false positives than traditional provocative tests using insulin, arginine, or clonidine, making it more specific for distinguishing hypothalamic from pituitary causes of GHD. Peroni et al. (2012) studied GH responses to growth hormone-releasing peptide-2 (GHRP-2) in GH-deficient and normal-stature children, noting that different secretagogues test different levels of the GH axis, with GHRH analogs (like sermorelin) testing pituitary reserve specifically.[4]
Spiliotis et al. (2008) explored a combined GHRH + GHRP-6 test, administering both a GHRH analog and a ghrelin-receptor agonist simultaneously to produce a synergistic GH response. This combination test proved more potent as a diagnostic stimulus than either agent alone and was proposed as a more reliable assessment of maximal pituitary secretory capacity.[5]
Why sermorelin was discontinued
Sermorelin (brand name Geref) was voluntarily withdrawn from the market by its manufacturer in 2008. The discontinuation was driven by commercial factors, not safety signals. No serious adverse events were identified in post-marketing surveillance. The most common side effects reported were transient facial flushing (occurring within minutes of injection and resolving spontaneously), pain at the injection site, and rare headache.
The commercial failure reflected several realities. First, rhGH was already well-established as the standard of care, with decades of pediatric data and robust prescriber familiarity. Sermorelin's inferior efficacy made it a hard sell to endocrinologists whose primary concern was maximizing height gain. Second, the pediatric GHD market was small, and sermorelin's niche within it (children with mild or hypothalamic-origin GHD) was smaller still. Third, compounding pharmacies began producing sermorelin off-label, eroding the branded product's market share.
The withdrawal of FDA-approved sermorelin had an unintended consequence: it shifted sermorelin use almost entirely to the compounding pharmacy market, where it is now widely prescribed off-label for adults seeking anti-aging or body composition benefits. For the adult use case and the broader growth hormone secretagogue landscape, see Sermorelin: The Original Growth Hormone Releasing Peptide.
The requirement for intact pituitary function
Sermorelin's fundamental limitation is that it cannot work without functional pituitary somatotroph cells. This restricts its use to GH deficiency caused by hypothalamic dysfunction (reduced GHRH signal reaching a capable pituitary) and excludes children with:
- Pituitary aplasia or hypoplasia: Anatomically absent or underdeveloped pituitary gland
- Post-surgical pituitary damage: Children who have undergone surgery for craniopharyngioma or other sellar tumors
- Post-radiation damage: Pituitary irradiation for brain tumors
- Congenital combined pituitary hormone deficiency: Multiple pituitary hormone deficits indicating broad somatotroph dysfunction
For these children, only direct GH replacement (rhGH) or, in cases of severe IGF-1 deficiency with GH insensitivity, mecasermin (recombinant IGF-1) is effective. See Mecasermin (IGF-1): Treating Severe Growth Failure and Growth Hormone Deficiency in Children: Peptide Treatment Options for these alternatives.
Campos et al. (2026) studied IGF-1 bioavailability in congenital isolated GH deficiency, demonstrating that the relationship between GH secretion and downstream IGF-1 levels is complex and varies by the specific genetic cause of GHD. This work underscores why one-size-fits-all approaches to GH stimulation fail: different etiologies of GHD respond differently to GHRH stimulation.[6]
GHRH analogs after sermorelin
Sermorelin's withdrawal did not end interest in GHRH-based therapeutics. Several next-generation approaches have been developed.
CJC-1295: A modified GHRH analog with a Drug Affinity Complex (DAC) that extends its half-life from minutes to approximately 6-8 days. Alba et al. (2006) showed that once-daily CJC-1295 administration produced sustained GH and IGF-1 elevation in healthy adults, a pharmacokinetic profile far superior to sermorelin's rapid clearance.[7] CJC-1295 has not been studied in pediatric populations and is not FDA-approved for any indication. For details, see How CJC-1295 Stimulates Growth Hormone: Mechanism of Action.
Modified GRF 1-29 (Mod GRF): A version of sermorelin with amino acid substitutions at positions 2, 8, 15, and 27 that improve metabolic stability without adding the DAC moiety. This compound has a half-life of approximately 30 minutes versus sermorelin's 10-20 minutes. See Mod GRF 1-29: The Short-Acting Version of CJC-1295.
GHRH agonist analogs: Cai et al. (2014) synthesized potent agonistic analogs of GHRH with enhanced receptor binding affinity and metabolic stability, intended for both GH-stimulating and potential anti-cancer applications.[8] Zarandi et al. (2017) continued this structure-activity work, developing novel GHRH analogs with modifications that resist enzymatic degradation while maintaining full agonist activity at the GHRH receptor.[9]
GHRP-2 and other ghrelin-type secretagogues: These peptides stimulate GH release through the ghrelin receptor (GHSR-1a) rather than the GHRH receptor, providing a complementary pathway. Pihoker et al. (1997) tested intranasal GHRP-2 in children with GH deficiency, demonstrating measurable GH release through a non-injection route.[10] For the oral secretagogue approach, see MK-677 (Ibutamoren): The Oral Growth Hormone Secretagogue.
What the sermorelin story teaches
Sermorelin's arc from FDA approval to market withdrawal within 11 years illustrates several recurring themes in peptide therapeutics.
The first is that physiological elegance does not guarantee clinical success. Sermorelin's mechanism was pharmacologically attractive: stimulate the body's own GH production, preserve pulsatile secretion, maintain feedback regulation. But clinicians needed maximum growth velocity in short-statured children, and rhGH delivered more height per year. Theoretical advantages in mechanism lost to practical advantages in outcome.
The second is that peptide half-life matters. Sermorelin's rapid clearance (half-life of 10-20 minutes) required nightly injections that produced a single GH pulse, while endogenous GHRH produces multiple pulses throughout the day. The development of longer-acting analogs like CJC-1295 addressed this limitation but came too late for the pediatric market.
The third is the compounding pharmacy effect. When branded sermorelin disappeared, the unregulated compounding market absorbed the demand, primarily for adult off-label use. This pattern has repeated with multiple peptides and raises ongoing questions about quality control, dose accuracy, and sterility in compounded formulations.
The Bottom Line
Sermorelin (GHRH 1-29) was the first GHRH analog approved for pediatric growth hormone deficiency, offering a mechanistically distinct alternative to recombinant GH by stimulating endogenous GH production from the pituitary. Clinical trials showed it increased height velocity in children with hypothalamic-origin GHD, but less effectively than rhGH. Its requirement for intact pituitary function limited the eligible population, and commercial factors led to its withdrawal in 2008. The drug's legacy is visible in the next-generation GHRH analogs (CJC-1295, Mod GRF 1-29) and in the ongoing compounding pharmacy market that absorbed demand after FDA-approved sermorelin disappeared.